New drug cocktail aims to shrink tumors before breast cancer surgery
NCT ID NCT07492394
Summary
This study is testing two different combinations of oral medications given before surgery (neoadjuvant therapy) for early-stage breast cancer that is hormone-sensitive. It aims to see if adding a third drug (entinostat) to a standard two-drug combo (dalpiciclib and letrozole) is more effective at shrinking tumors. The goal is to improve outcomes and potentially allow for less extensive surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.